Huang James, 03 Life Sciences Disclose Significant Adagene Stake

Ticker: ADAG · Form: SC 13G · Filed: 2024-01-19T00:00:00.000Z

Sentiment: neutral

Topics: insider-ownership, institutional-holding, SC-13G

Related Tickers: ADAG

TL;DR

**Huang James and Panacea funds just revealed a big stake in Adagene, watch for potential influence.**

AI Summary

On January 18, 2024, Huang James, associated with 03 Life Sciences, filed an SC 13G indicating a significant ownership stake in Adagene Inc. (NASDAQ: ADAG). This filing, under Rule 13d-1(c), signals that Huang James and his affiliated group, including Panacea Innovation Ltd and Panacea Venture Healthcare Fund II, now hold a substantial position in the pharmaceutical company. This matters to investors because large institutional or individual holdings can influence company direction and signal confidence (or lack thereof) in the stock's future performance.

Why It Matters

This filing reveals a notable ownership position by a key individual and associated funds, which can impact investor sentiment and potentially influence Adagene's strategic decisions.

Risk Assessment

Risk Level: low — This filing indicates a significant ownership stake, which is generally a neutral to positive signal, not an immediate risk.

Analyst Insight

Investors should monitor future filings from Huang James and the Panacea group for any changes in their Adagene Inc. holdings, as significant increases or decreases could signal their evolving outlook on the company.

Key Numbers

Key Players & Entities

Forward-Looking Statements

FAQ

Who filed this SC 13G statement regarding Adagene Inc.?

The SC 13G statement was filed by Huang James, associated with 03 Life Sciences, and includes group members PANACEA INNOVATION LTD, PANACEA VENTURE HEALTHCARE FUND II GP COMPANY, LTD., and PANACEA VENTURE HEALTHCARE FUND II, L.P.

What is the CUSIP number for Adagene Inc.'s securities mentioned in the filing?

The CUSIP number mentioned is 005329 107, which is assigned to the American depositary shares (ADSs) of Adagene Inc., traded on NASDAQ under the symbol "ADAG."

What was the date of the event that required this SC 13G filing?

The date of the event which required the filing of this statement was January 18, 2024.

Under which rule was this Schedule 13G filed?

This Schedule 13G was filed under Rule 13d-1(c).

What is the relationship between Adagene's American Depositary Shares (ADSs) and its ordinary shares?

Each American Depositary Share (ADS) of Adagene Inc. represents one and one quarter ordinary shares, with a par value of US$0.0001 per share.

From the Filing

0001193125-24-010782.txt : 20240119 0001193125-24-010782.hdr.sgml : 20240119 20240119083757 ACCESSION NUMBER: 0001193125-24-010782 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20240119 DATE AS OF CHANGE: 20240119 GROUP MEMBERS: PANACEA INNOVATION LTD GROUP MEMBERS: PANACEA VENTURE HEALTHCARE FUND II GP COMPANY, LTD. GROUP MEMBERS: PANACEA VENTURE HEALTHCARE FUND II, L.P. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Adagene Inc. CENTRAL INDEX KEY: 0001818838 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-92270 FILM NUMBER: 24543812 BUSINESS ADDRESS: STREET 1: 4F, BUILDING C14, NO. 218, XINGHU STREET STREET 2: SUZHOU INDUSTRIAL PARK CITY: JIANGSU STATE: F4 ZIP: 00000 BUSINESS PHONE: 86-512-87773632 MAIL ADDRESS: STREET 1: 4F, BUILDING C14, NO. 218, XINGHU STREET STREET 2: SUZHOU INDUSTRIAL PARK CITY: JIANGSU STATE: F4 ZIP: 00000 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Huang James CENTRAL INDEX KEY: 0001573160 ORGANIZATION NAME: FILING VALUES: FORM TYPE: SC 13G MAIL ADDRESS: STREET 1: 9620 MEDICAL CENTER DRIVE STREET 2: SUITE 300 CITY: ROCKVILLE STATE: MD ZIP: 20850 SC 13G 1 d726976dsc13g.htm SC 13G SC 13G Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Adagene Inc. (Name of Issuer) Ordinary Shares (Title of Class of Securities) 005329 107** (CUSIP Number) January 18, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☒ Rule 13d-1(c) ☐ Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. ** There is no CUSIP number assigned to the ordinary shares. CUSIP number 005329 107 has been assigned to the American depositary shares (“ADSs”) of the Issuer, which are quoted on NASDAQ Stock Market under the symbol “ADAG.” Each ADS represents one and one quarter ordinary shares, par value US$0.0001 per share. The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. G1933S101 Schedule 13G Page 1 of 9 1 Names of Reporting Persons Panacea Venture Healthcare Fund I I, L.P. 2 Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐ 3 SEC Use Only 4 Citizenship or Place of Organization Cayman Islands Number of Shares Beneficially Owned by Each Reporting Person With 5 Sole Voting Power 0 6 Shared Voting Power 2 , 750 , 000 7 Sole Dispositive Power 0 8 Shared Dispositive Power 2 , 750 , 000 9 Aggregate Amount Beneficially Owned by Each Reporting Person 2 , 750 , 000 10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares Not Applicable 11 Percent of Class Represented by Amount in Row 9 5.0 % 12 Type of Reporting Person PN CUSIP No. 005329 107 Schedule 13G Page 2 of 9 1 Names of Reporting Persons Panacea Venture Healthcare Fund II GP Company, Ltd. 2 Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐ 3 SEC Use Only 4 Citizenship or Place of Organization Cayman Islands Number of Shares Beneficially Owned by Each Reporting Person With

View on Read The Filing